ClinicalTrials.gg
Status unknownNCT03260634Updated Aug 24, 2017

The Study of Voriconazole Trough Level in the First Two Weeks After Administration in King Chulalongkorn Memorial Hospital.

An observational study in Voriconazole and Fungal Infection, sponsored by Chulalongkorn University. Status unknown at 1 site in Thailand. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-24.

Sponsored by Chulalongkorn University · Observational

The sponsor has not verified this record recently (last verified Jan 2017), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
92
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Invasive fungal infections are a significant cause of morbidity and mortality in immunocompromised host such as prolong neutropenic patients , post transplantation patients, malignancies or advanced AIDS . The majority of these infections were caused by Aspergillus species, which the first line of treatment is antifungal agent, Voriconazole , a triazole antifungal drug which was approved by the Food and Drug Administration in May 2002 for the treatment of invasive aspergillosis and refractory infections of Scedosporium apiospermum and Fusarium spp. There are two forms of Voriconazole , oral and intravenous form. The recommendation dose is 6 mg/kg twice daily for two dosages, followed by 4 mg/kg twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals \<40 kg the maintenance dose is 100 mg twice daily in oral form.

Voriconazole has a narrow therapeutic window and nonlinear pharmacokinetic profile with wide inter-individual and intra-individual variability, such as age, race, genotypic variation, liver dysfunction, the presence of food and drug-drug interactions with CYP450 inhibitors. These large variations in pharmacokinetics may be associated with decreased efficacy or increased toxicity. Therefore , monitoring of serum trough concentrations is recommended in the following infections: invasive aspergillosis treatment , endophthalmitis; meningitis or osteoarticular infections due to Exserohilum rostratum.

In Thai population , there are different genetic polymorphism from Caucasian ,resulting in a different response to the initial dose and there is limited resources in Thailand , mostly patients are unaccessible for Voriconazole level. Especially,in the period of starting drug, which is the critical period for patients ,most of them are post chemotherapy which may have gastrointestinal problems, mucositis , vomiting or diarrhea ,as well as receiving multiple concurrent medications. All of these affect drug absorption,drug level and efficacy of treatment. Thus, this study was designed to evaluated Voriconazole level in Thai patients in the first two week after administration.

Primary question

  • From the first collected of Voriconazole drug level , Are the invasive fungal infection patients in King Chulalongkorn Memorial Hospital achieved the drug level more than 60% ?

Secondary question

  • Which factor affecting Voriconazole through level in the first two weeks after administration?

Research Design

  • Observational Studies (Descriptive retrospective and prospective study)

Research Methodology

Target Population

  • Patients received Voriconazole for treatment or prophylaxis invasive fungal infection

Study population

  • Patients in King Chulalongkorn Memorial hospital received Voriconazole for treatment or prophylaxis invasive fungal infection

Sample size

n= ZZ/2P(1-P) /dd

  • n = sample size
  • P =Incident rate
  • From the pilot study of 15 Invasive fungal infection patients in King Chulalongkorn memorial hospital from February to September 2015 , 60% ( 9 of 15 patients) of the first collected of Voriconazole trough level achieved the therapeutic level.

replaced P = 0.6

  • Z = 95% confident interval = 1.96
  • d = acceptable error = 0.10

n = (1.96) (1.96) (0.60)(1-0.60) / (0.10)(0.10)

n =92 , sample size = 92

Study processing and data collection

Data collection

  • Collected data of patients received Voriconazole in first two weeks of treatment or prophylaxis invasive fungal infection in King Chulalongkorn Memorial hospital in 2015-2017 from outpatient records , inpatient records and computer database in King Chulalongkorn Memorial hospital. This data included
  • Baseline characteristics : sex, age ,weight ,BMI ,co-morbid ,personal history of smoking or alcohol drinking
  • Basic laboratory investigation : complete blood count , Creatinin , liver function test , albumin level
  • Gastrointestinal problems
  • Indication of Voriconazole treatment
  • Data of invasive fungal infection :
  • Data of Voriconazole usage : Loading dose, Maintenance dose, Trough level , Data of drug adjustment, Concurrent medication used, Side effect
  • All data was summarized and recorded in case report forms.

Data Analysis and Statistics

The data was analysed by computer using SPSS17 program This study used descriptive statistics ,describing general information, age, results, laboratory results and side effects of the drug in mean ,percentage or standard deviation. And used the chi-square test for analysis of the proportion of patients with serum drug levels within the therapeutic range.

This study used a confidence level of 95%, p-value less than 0.05 was statistically significant.

02

Conditions studied

  • Voriconazole
  • Fungal Infection

Browse trials for

Keywords

  • voriconazole
  • therapeutic drug monitoring
03

In context

Mycoses

260 studies on the registry are indexed under Mycoses; 37 are open to participants now.

This study's planned enrollment of 92 is below the median of 153 across 85 observational studies indexed under Mycoses.

Browse Mycoses studies →

Lead sponsor

Chulalongkorn University is the lead sponsor of 322 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Thai patient in King Chulalongkorn Memorial Hospital ,Bangkok , Thailand, age between 18 and 80 year olds ,receiving Voriconazole for treatment or prophylaxis invasive fungal infection , between 2015-2017.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Thai patient in King Chulalongkorn Memorial Hospital , age between 18 and 80 years old
  • Receiving Voriconazole for treatment or prophylaxis invasive fungal infection

Exclusion criteria

Exclusion Criteria:

  • Severe hepatic or renal dysfunction
  • Pregnancy
  • Presence of history of allergy to any Azole antifungal agents
  • Death within 2 weeks after treatment of invasive fungal infection
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
92 participants (estimated)
Patient registry
No

Groups and cohorts

  • Voriconazole

    Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals \>40 kg), followed by 200 mg twice daily, and in individuals \<40 kg the maintenance dose is 100 mg twice daily in oral form. The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment.

    Drug: Voriconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients achieved therapeutic level of voriconazole in the first two weeks after administration

    Time frame: 2015-2017

Secondary outcomes

  1. Factors have significant impact to voriconazole through level .

    Factors that have significant impact to voriconazole through level will be assess in this study such as drug interaction , oral mucositis .

    Time frame: 2015-2017

07

Study locations

1 site
  • Chulalongkorn university
    Bangkok, 10330, Thailand
08

References and documents

Publications

  • Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, Ohmagari N, Takahashi Y, Kasahara K, Matsumoto K, Okada K, Igarashi M, Kobayashi M, Mochizuki T, Nishi Y, Tanigawara Y, Kimura T, Takesue Y. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013 Jun;19(3):381-92. doi: 10.1007/s10156-013-0607-8. Epub 2013 May 15. No abstract available. PubMed 23673473 ↗
  • Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012 Oct;55(8):1080-7. doi: 10.1093/cid/cis599. Epub 2012 Jul 3. PubMed 22761409 ↗
  • Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008 Jan 15;46(2):201-11. doi: 10.1086/524669. PubMed 18171251 ↗
  • Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006 Feb;46(2):235-43. doi: 10.1177/0091270005283837. PubMed 16432276 ↗
  • Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, Kurokawa M. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009 Jun;89(5):592-9. doi: 10.1007/s12185-009-0296-3. Epub 2009 Apr 2. PubMed 19340528 ↗
  • Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29. PubMed 27365388 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2016 (actual). Primary completion is estimated for Oct 2017, 21 months after the start.

Of 28 observational studies under Mycoses, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Aug 24, 2017
StartActual
Jan 1, 2016
Primary completionEst.
Oct 1, 2017
CompletionEst.
Jan 1, 2018
Last update
Aug 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03260634
Responsible party
Sponsor
First posted
Aug 24, 2017
Start date
Jan 1, 2016
Primary completion
Oct 1, 2017 (estimated)
Completion
Jan 1, 2018 (estimated)
Last update
Aug 24, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion